Bal Pharma Management
Management criteria checks 3/4
Bal Pharma's CEO is Shailesh Siroya, appointed in Aug 2019, has a tenure of 5.42 years. total yearly compensation is ₹10.20M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 19.27% of the company’s shares, worth ₹357.69M. The average tenure of the management team and the board of directors is 4.3 years and 4.7 years respectively.
Key information
Shailesh Siroya
Chief executive officer
₹10.2m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 5.4yrs |
| CEO ownership | 19.3% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet
Sep 19
Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 18Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet
Sep 19Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20
Aug 31Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Aug 27Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year
Aug 15Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price
May 30Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up
Feb 01Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 18Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00
Aug 28Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 14Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 17Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00
Jul 31Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?
Mar 08Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky
Nov 23Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?
Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?
Aug 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹77m |
| Jun 30 2024 | n/a | n/a | ₹76m |
| Mar 31 2024 | ₹10m | ₹10m | ₹74m |
| Dec 31 2023 | n/a | n/a | ₹35m |
| Sep 30 2023 | n/a | n/a | ₹32m |
| Jun 30 2023 | n/a | n/a | ₹24m |
| Mar 31 2023 | ₹12m | ₹12m | ₹26m |
| Dec 31 2022 | n/a | n/a | ₹29m |
| Jun 30 2022 | n/a | n/a | ₹43m |
| Mar 31 2022 | ₹10m | ₹10m | ₹56m |
| Dec 31 2021 | n/a | n/a | ₹72m |
| Jun 30 2021 | n/a | n/a | ₹59m |
| Mar 31 2021 | ₹10m | ₹10m | ₹47m |
| Dec 31 2020 | n/a | n/a | -₹34m |
| Sep 30 2020 | n/a | n/a | -₹73m |
| Jun 30 2020 | n/a | n/a | -₹95m |
| Mar 31 2020 | ₹10m | ₹10m | -₹122m |
| Dec 31 2019 | n/a | n/a | -₹52m |
| Sep 30 2019 | n/a | n/a | -₹15m |
| Jun 30 2019 | n/a | n/a | -₹21m |
| Mar 31 2019 | ₹8m | ₹8m | ₹38m |
| Dec 31 2018 | n/a | n/a | ₹29m |
| Mar 31 2018 | ₹8m | ₹8m | ₹28m |
Compensation vs Market: Shailesh's total compensation ($USD118.59K) is above average for companies of similar size in the Indian market ($USD41.93K).
Compensation vs Earnings: Shailesh's compensation has been consistent with company performance over the past year.
CEO
Shailesh Siroya (58 yo)
5.4yrs
Tenure
₹10,200,000
Compensation
Mr. Shailesh Dheerajmal Siroya serves as the Managing Director of BAL Pharma Limited. Mr. Siroya served as the Managing Director of BAL Pharma Limited since August 1, 1994. With rich experience, Mr. Siroya...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 5.4yrs | ₹10.20m | 19.27% ₹ 357.7m | |
| Chief Financial Officer | no data | ₹2.60m | no data | |
| Company Secretary & Compliance Officer | 1.5yrs | ₹540.00k | no data | |
| Whole Time Director | 4.3yrs | ₹3.32m | 0.17% ₹ 3.1m | |
| Deputy General Manager of Internal Audit | no data | no data | no data | |
| Assistant Vice President of Sales & Marketing | no data | no data | no data | |
| Vice President of International Marketing & HR | no data | ₹534.34k | no data | |
| Whole Time Director | no data | ₹1.87m | no data |
4.3yrs
Average Tenure
59.5yo
Average Age
Experienced Management: BALPHARMA's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 27.3yrs | ₹10.20m | 19.27% ₹ 357.7m | |
| Whole Time Director | 5.3yrs | ₹3.32m | 0.17% ₹ 3.1m | |
| Whole Time Director | 2.7yrs | ₹1.87m | no data | |
| Independent Non-Executive Director | 4.7yrs | ₹52.00k | no data | |
| Non-Executive Additional Independent Director | 4.7yrs | ₹61.00k | no data | |
| Non-Executive Independent Director | 4.1yrs | ₹61.00k | no data |
4.7yrs
Average Tenure
63yo
Average Age
Experienced Board: BALPHARMA's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:51 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bal Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|